Intranasal T-LysYal® as adjunctive therapy for patients after functional endoscopic sinus surgery

M. Gelardi, S. Taliente, M.L. Fiorella, N. Quaranta, N. De Candia, C. Russo, P. Mola, A. Ciofalo, G. Zambetti, E. Cantone, F. Arnone, A. Macchi, P. Rosso, G. Ciprandi

Article ID: 4074
Vol 30, Issue 1, 2016
DOI: https://doi.org/10.54517/jbrha4074
Received: 6 June 2022; Accepted: 6 June 2022; Available online: 6 June 2022; Issue release: 6 June 2022

Abstract

Functional Endoscopic Sinus Surgery (FESS) is a common day surgery technique for upper airway disorders. Hyaluronic acid (HA) is a fundamental component of the human connective tissue. HA may exert reparative, anti-inflammatory and immune-modulating activities. Recently, a new intranasal HA formulation has been proposed: a supramolecular system containing lysine hyaluronate, thymine and sodium chloride (T-LysYal®). This randomized study investigated whether intranasal T-LysYal® (RinoLysYal®, Farmigea, Italy) was able to reduce symptom severity, endoscopic features, and nasal cytology in 83 patients (49 males and 34 females mean age 45.4±6.2 years) treated with FESS. All patients were treated with isotonic saline solution for 4 weeks, and a sub-group (active group) was also treated with intranasal T-LysYal®. Patients were visited at baseline, after treatment, and after 4-week follow-up. Intranasal T-LysYal® treatment significantly reduced the quote of patients with symptoms, endoscopic features, and inflammatory cells in comparison to isotonic solution. In conclusion, the present study demonstrates that intranasal T-LysYal® is able to significantly improve patients after FESS and its effect is long lasting.


Keywords

intranasal T-LysYal®;FESS;nasal symptoms;endoscopy;nasal cytology


References

Supporting Agencies



Copyright (c) 2016 M. Gelardi, S. Taliente, M.L. Fiorella, N. Quaranta, N. De Candia, C. Russo, P. Mola, A. Ciofalo, G. Zambetti, E. Cantone, F. Arnone, A. Macchi, P. Rosso, G. Ciprandi




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).